Simon J. Crabb, PhD, MBBS, on Urothelial Carcinoma: Switch Maintenance Therapy With Rucaparib Following Chemotherapy

March 03, 2022 By The ASCO Post Staff

Simon J. Crabb, PhD, MBBS, of the Southampton Experimental Cancer Medicine Centre, discusses data from the ATLANTIS trial, in which the authors hypothesized that switch maintenance therapy with the PARP inhibitor rucaparib, in patients who have derived clinical benefit from first-line chemotherapy, may improve outcomes for those with metastatic urothelial carcinoma that harbored a composite biomarker for DNA repair deficiency (Abstract 436).

Related Content